Dimension Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Dimension Bio is a private, preclinical-stage biotech founded in 2021 and headquartered in Cambridge, USA, with a significant operational presence in Chicago. The company is developing a novel class of regenerative 'tissue therapeutics' using its proprietary BioNidum™ platform, which combines cells with a 3D-printed biomaterial matrix to enhance cell survival, integration, and function. With a lead program in acute-on-chronic liver failure and a platform validated through partnerships and a prior FDA-cleared bone graft product, Dimension Bio is positioned at the intersection of advanced biomaterials, cell therapy, and digital manufacturing. The company has raised a $12M Series A and is backed by a strong team and advisory boards with deep expertise in biomaterials and hepatology.

Liver FailureRegenerative Medicine

Technology Platform

BioNidum™: A bioinspired cell delivery system that fuses materials science, 3D-printing, and digital manufacturing to create 3D implantable matrices designed to promote cell survival, vascularization, and tissue integration.

Opportunities

The massive unmet need in organ failure, particularly liver disease where transplant organs are scarce, presents a multi-billion dollar addressable market.

The BioNidum™ platform's versatility also allows for potential expansion into regenerating other tissues, such as bone (already validated), pancreas, or kidney, creating a broad pipeline from a single core technology.

Risk Factors

The company faces high technical and clinical risk in translating a complex cell-plus-scaffold therapy from preclinical models to humans.

Regulatory pathways for such novel combination products are uncertain and lengthy.

As a preclinical, private company, it is also dependent on raising significant additional capital in a competitive financing environment.

Competitive Landscape

Dimension Bio competes in the regenerative medicine space against pure-play cell therapy companies, traditional tissue engineering firms, and developers of artificial organ assist devices. Its key differentiation is the integrated BioNidum™ platform, which aims to solve cell delivery and integration challenges that have limited earlier cell therapies. Competition is intense from larger, well-funded biotechs and academic spin-outs pursuing similar biofabrication goals.

More companies in Regenerative Medicine →More companies in United States →